You are here

Regeneron

Novartis trial results could spell trouble for Regeneron

Novartis trial results could spell trouble for Regeneron

Drug Delivery Business News

clinical trials

neovascular age-related macular degeneration

Flag link:

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

Market Realist

Flag link:

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Endpoints

Flag link:

Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics

Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics

Fierce Pharma

LDL cholesterol

Flag link:

Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick

Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick

Motley Fool

Flag link:

Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price

Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price

Fierce Pharma

rheumatoid arthritis

Flag link:

Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms

Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms

Fierce Biotech

Vertex Pharmaceuticals

Flag link:

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Fierce Pharma

Flag link:

Regeneron posts mixed Q1 results, Eylea growth slows

Regeneron posts mixed Q1 results, Eylea growth slows

Drug Delivery Business News

Flag link:

5 Big Drugmakers With Important Catalysts in May

5 Big Drugmakers With Important Catalysts in May

Motley Fool

nonacog beta pegol

Flag link:

Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

Market Realist

Flag link:

Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum

Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum

Endpoints

Leonard Schleifer

Flag link:

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Yahoo

Flag link:

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

Yahoo/Reuters

rheumatoid arthritis

Flag link:

Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain

Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain

Motley Fool

rheumatoid arthritis

Flag link:

When do pharmas disclose launch prices up front? When they’re pricing at a discount

When do pharmas disclose launch prices up front? When they’re pricing at a discount

Fierce Pharma

Flag link:

3 Big Biotech Stocks With Big-Time Catalysts

3 Big Biotech Stocks With Big-Time Catalysts

Motley Fool

Flag link:

The stellar antibody shop at Regeneron wins a ‘breakthrough’ tag for its next big PhIII drug

The stellar antibody shop at Regeneron wins a ‘breakthrough’ tag for its next big PhIII drug

Endpoints

breakthrough therapies

LDL cholesterol

Flag link:

How a $37,000-a-year medicine sets a good model for drug pricing

How a $37,000-a-year medicine sets a good model for drug pricing

Stat

Flag link:

Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't

Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't

Fierce Pharma

PCSK9 inhibitors

Flag link: